SGLT-2 inhibitors, a relatively new group of drugs primarily used in patients with type 2 diabetes (Table 1, Figure 4), may have a transient impact on calcium and phosphorus homeostasis. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.